|| List of recent Peptide-related patents
|Polypeptides having endoglucanase activity and polynucleotides encoding same|
Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Plants having enhanced yield-related traits and producing methods thereof|
Provided is a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a hhh-gpd-related polypeptide, or a calnexin-related polypeptide. Also provided are plants having modulated expression of a nucleic acid encoding a hhh-gpd-related polypeptide, or a calnexin-related polypeptide, which plants have enhanced yield-related traits relative to control plants..
|Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides|
This invention is in the field of plant molecular biology. More specifically, this invention pertains to isolated nucleic acid fragments encoding pae or pae-like proteins in plants and seeds and the use of such fragments to modulate expression of a gene encoding pae or pae-like protein activity in a transformed host cell..
|Gene and mutations thereof associated with seizure and movement disorders|
The present invention relates to the proline rich transmembrane protein 2 (prrt2) gene, and the identification of mutations and variations in prrt2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the prrt2 gene.
|Laser assisted delivery of functional cells, peptides and nucleotides|
The present invention relates to methods, uses, systems and kits for laser-assisted delivery of at least one bioactive agent to a subject. Specifically, laser light is used to create channel(s) in tissue of the subject, and the bioactive agent (s) is applied to the opening of the channel(s).
|Method for the stereoselective preparation of amino acid derivatives|
The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (iii), alternatively its enantiomer, wherein r is (c1-c8)-alkyl; followed by a hydrolysis reaction to obtain l-mesityl alanine, alternatively its enantiomer d-mesityl alanine and, optionally, subjecting said compound to an amino group protection reaction, particularly as fmoc. It also comprises fmoc-l- or fmoc-d- mesityl alanine as products per se, useful as intermediates in preparing peptides or peptide analogs with therapeutic or biological activity..
|Arthropod pest control composition and method|
A composition to affect an arthropod is described that may include a fatty alcohol, a surface active agent, and a carrier. The composition may include substantially no oil and interrupts production of adipokinetic hormones (akh) in the arthropod.
|Targeting gli proteins in human cancer by small molecules|
The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a gli polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof..
|Micro-utrophin polypeptides and methods|
Described herein are polypeptides, polynucleotides and methods involving a μ-utrophin region or an anti-dystrophinopathic fragment thereof operationally linked to a second region effective to transduce the fusion protein into mammalian muscle cells.. .
|Hsp20 inhibits amyloidogenesis and neurotoxicity|
The present invention compositions and methods of using at least a portions of an isolated and purified α-crystallin polypeptide that includes one or more β-pleated sheets and that prevents neurotoxicity and amyloidogenesis.. .
|Pro-coagulant compounds and methods of use thereof|
Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from fix, fviia, fviii, and platelet targeting moieties (e.g., pdg-13), wherein the compound is linked to the polypeptide optionally via a linker.
The invention relates to a derivative of a glp-1 peptide, which peptide has two lys residues, namely a first and a second lys residue, and a maximum of eight amino acid changes as compared to glp-1(7-37) (seq id no: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second lys residue, respectively, via a linker, wherein the protracting moiety is selected from chem. 15: hooc—(ch2)x-co—*, and chem.
|N-acyldipeptide derivatives and their uses|
N-acyldipeptide derivatives are described. Compositions comprising the n-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject..
|Non-standard insulin analogues|
An insulin analogue comprises a b-chain polypeptide containing a cyclohexanylalanine substitution at position b24 and optionally containing additional amino-acid substitutions at positions a8, b28, and/or b29. A proinsulin analogue or single-chain insulin analogue containing a b domain containing a cyclohexanylalanine substitution at position b24 and optionally containing additional amino-acid substitutions at positions a8, b28, and/or b29.
|Cyclic antimicrobial peptides|
The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.. .
|Anti-microbial peptides and methods of use thereof|
Anti-microbial peptides and methods of use are provided.. .
|Nucleic acid assembly system|
The present invention relates to a method for the preparation of a library of host cells, a plurality of which comprise an assembled polynucleotide at a target locus, which method comprises: (a) providing a plurality of polynucleotides comprising two or more polynucleotide subgroups, wherein: (i) a plurality of polynucleotides in each polynucleotide subgroup comprises sequence encoding a peptide or polypeptide and/or a regulatory sequence; (ii) a plurality of peptides or polypeptides encoded by, or a plurality of regulatory sequences comprised within, each polynucleotide subgroup share an activity and/or function; (iii) at least one polynucleotide subgroup comprises at least two non-identical polynucleotide species; (iv) a plurality of polynucleotides of each polynucleotide subgroup comprises sequence enabling homologous recombination with a plurality of polynucleotides from one or more other polynucleotide subgroups; and (v) a plurality of polynucleotides in two polynucleotide subgroups comprise a nucleotide sequence enabling homologous recombination with a target locus in host cells; and (b) assembling the plurality of polynucleotides at the target locus by homologous recombination in vivo in host cells, thereby to generate a library of host cells, a plurality of which comprise an assembled polynucleotide at the target locus. The assembled polynucleotides may be recovered, thereby to prepare a library of nucleic acids..
|Propeptide-luciferase fusion proteins and methods of use thereof|
The present invention provides nucleic acid constructs that encode fusion peptides comprising a bioluminescent protein and a precursor of a secreted peptide or protein expressed at the cell surface and high throughput screening assays using same.. .
|Magnetic-nanoparticle conjugates and methods of use|
The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse.
|Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor|
[solution] a method for assessing whether or not there is a predisposition for the occurrence of myelodysplastic syndrome or myeloid tumor, wherein the method comprises a step for using a sample that includes a subject's human genes and detecting a mutation in at least one gene from among the u2af35 gene, the zrsr2 gene, the sfrs2 gene, or the sf3b1 gene. The assessment is that there is a predisposition for the occurrence of myelodysplastic syndrome or myeloid tumor when at least one of the following is detected: a substitution from s to f or y at amino acid 34 of a protein translated from the u2af35 gene; a substitution from q to r or p at amino acid 157 of a protein translated from the u2af35 gene; any inactivating mutation of a protein translated from the zrsr2 gene, a substitution from p to h, l, or rat amino acid 95 of a protein translated from the sfrs2 gene; or a substitution from k to e at amino acid 700, a substitution from e to d at amino acid 622, a substitution from h to q or d at amino acid 662, or a substitution from k to n, t, e, or r at amino acid 666 of a protein translated from the sf3b1 gene.
|Methods and compositions for species-specific kinome microarrays|
A method of preparing a species-specific phosphorylation site peptide array for a target organism comprising: a) selecting a plurality of known non-target organism (nto) phosphorylation site sequences and cognate known nto phosphorylation polypeptide sequences from one or more nto, each of the known nto phosphorylation site sequences comprising at least 5 residues and less than 30 residues; b) identifying a matching target organism (to) phosphorylation site sequence and cognate to phosphorylation polypeptide sequence for one or more of the known nto phosphorylation site sequences; c) determining the matching to phosphorylation site sequences that correspond to orthologue polypeptides of the cognate known nto phosphorylation polypeptide sequences; d) selecting the matching to phosphorylation site sequences determined to correspond to orthologue polypeptides for inclusion on the array; wherein the matching to phosphorylation site sequences that correspond to orthologue polypeptides are determined by calculating, for each matching phosphorylation site sequence identified in b), a similarity value between the to phosphorylation polypeptide sequence corresponding to the to phosphorylation site sequence and a to polypeptide sequence matching the cognate known nto polypeptide sequence.. .
|Akt-specific capture agents, compositions, and methods of using and making|
The present application provides stable peptide-based akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including akt capture agents, using iterative on-bead in situ click chemistry..
|Polydnavirus delivery constructs|
Provided herein are methods of producing a genetically modified cell by introducing a polydnavirus delivery construct to a target cell. The polydnavirus delivery construct can comprise an exogenous nucleic acid to form a genetically modified cell comprising the exogenous nucleic acid.
|3-hydroxypropionic acid and other organic compounds|
Methods and materials related to producing 3-hp as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-hp and other organic compounds are disclosed..
|Reduced genome bacteria with improved genetic stability|
Reduced genome bacteria with improved genetic stability are provided. Also provided are methods of producing polypeptides using the reduced genome bacteria with improved genetic stability..
|Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues|
Disclosed herein is pyrroline-carboxy-lysine (pcl), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating pcl. Also disclosed herein are proteins, polypeptides and peptides that have pcl incorporated therein and methods for incorporating pcl into such proteins, polypeptides and peptides.
|Enzyme treatment apparatus for proteins using a hollow fiber membrane, and on-line proteomics method using same|
Provided are an enzyme treatment apparatus for proteins using a hollow fiber membrane and an on-line proteomics method using same. The enzyme treatment apparatus for proteins according to the present invention can increase a recovery rate of peptides, which are recovered through an enzyme treatment process, by basically solving the problem of low reproducibility of an enzyme activity which may occur during a conventional enzyme treatment process, and can also reduce a time for purification and provide higher yield by performing separation and purification through a single step.
|Diagnosis of pulmonary and/or cardiovascular disease|
Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (cvd) or pulmonary disease (pd) in a subject using st2/interleukin 1 receptor like 1 (il1rl1) and/or interleukin 33 (il-33), and a biomarker for cvd, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (bnp), prohormone bnp (probnp), n-terminal probnp (nt-probnp), atrial natriuretic peptide (anp), proanp, or nt-proanp.. .
|Anti-canine n-terminal pro-atrial natriuretic peptide antibody, and immunological measurement method and immunologically measuring kit using the same|
The anti-canine n-terminal pro-atrial natriuretic peptide antibodies (anti-canine nt-proanp antibodies) according to the present invention comprise anti-canine nt-proanp recognizing a partial portion or a whole portion of the amino acid sequence 31 to 67 of canine nt-proanp and anti-canine nt-proanp recognizing a partial portion or a whole portion of the amino acid sequence 68 to 98 thereof. The anti-canine nt-proanp antibodies are useful for immunologically measuring canine nt-proanp involved in heart diseases and infections of companion animals such as dogs, such as heart failure, mitral valve insufficiency and filariasis.
|Methods of identifying senp1 inhibitors|
Provided herein are methods of detecting binding of an senp1 polypeptide to a compound and methods for screening for inhibitors of senp1. Further provided are aqueous compositions comprising senp1 polypeptides and nmr apparatuses comprising the compositions for nmr analysis..
|Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor|
The present disclosure provides lysyl oxidase-like-2 (loxl2) polypeptide binding agents, including, for example, antibodies that specifically bind a loxl2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided..
|Anti-idiotype antibody against anti-c-met antibody|
Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-met antibody, the use of the anti-idiotype antibody for detecting the anti-c-met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.. .
|Rapid detection of the "high virulent" st-17 clone of group b streptococcus|
The present invention also relates to kits and methods for the specific detection of group b streptococcus highly-virulent st-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.. .
|Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof|
The invention relates to a polypeptide of a protective antigenic determinant (pad polypeptide) of porcine reproductive and respiratory syndrome virus (prrsv) and nucleic acids encoding a pad polypeptide. The pad polypeptide and nucleic acids encoding a pad polypeptide are useful in the development of antibodies directed to pad, vaccines effective in providing protection against prrsv infection, and diagnostic assays detecting the presence of pad antibodies generated by a pad-specific vaccine.
|Method for the formulation of a gel-format foodstuff for use as a nutritional foodstuff enriched with peptides and maltodextrins obtained from quinoa flour|
Disclosed is a process to extract peptides and maltodextrins from quinoa flour for the manufacturing of foodstuff corresponding to a gel for sportspeople consumption during and after physical activity.. .
|Cysteine peptide-containing health drink|
An object is to provide a health drink which gives a real feeling of a preventive effect and ameliorative effect against skin aging and stress, and it is confirmed that when a drink in which glutathione is added to a conventional drink containing chondroitin, hyaluronic acid, and vitamins is taken, a concentration of blood dhea-s, which is considered to be an indicator of rejuvenation, is significantly elevated, promoting gene expressions of olfactory receptors and the like, and remarkably ameliorating skin condition, total mood disturbance, autonomic nerve balance, and overall health condition.. .
|Methods and compositions for treating pain|
Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent.
|Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies|
The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts.
|Nanotubes and compositions thereof|
The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.. .
|Mycobacterium tuberculosis porins and toxins and related methods|
Provided herein are isolated polypeptides comprising the amino-terminal domain of mycobacterium tuberculosis porin a (mtpa), wherein the polypeptide is a porin monomer. Also provided are isolated polypeptides comprising the carboxy-terminal domain of mycobacterium tuberculosis porin a, wherein the polypeptide is a toxin.
There is provided a netb epitope polypeptide comprising at least 10 contiguous amino acids from seq id no:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in seq id the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to seq id no:1 and having reduced toxicity compared with the toxicity of seq id no:1. The polypeptide is useful to vaccinate a subject against infection by clostridium perfringens..
|Use of gk-1 peptide expressed on m13 filamentous phage as pharmaceutical ingredient to enhance the efficiency of the immune response induced by vaccine or pathogen antigens|
The present invention is directed to the use of fgk-1 immunopotentiator, composed by the peptide named gk-1, characterized by the sequence g-y-y-y-p-s-d-p-n-t-f-y-a-p-p-y-s-a and linked to the pviii surface protein of m13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchoalveolar lavages.. .
|Immunogenic protein conjugates and method for making and using the same|
Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided.
|Porphyromonas gingivalis polypeptides and nucleotides|
The present invention relates to isolated porphyromanas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: seq.
|Hiv-1 gp120 mini v3 loop and uses thereof|
The invention relates to an immunogenic hiv-1 gp120 mini v3 loop, which is a truncated version of the full-length gp120 v3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom.
|Haemophilus influenzae type b|
Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
The present invention provides aspartyl-trna synthetase derived proteins (drs polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The drs polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability..
|Immunogenic protein pas n 1 from bahia grass pollen|
The present invention relates generally to novel recombinant polypeptides of bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same.
|Non-natural mic proteins|
This invention describes soluble, monovalent, non-natural protein molecules that can activate nk cells and certain t-cells to attack specific cellular target cells by attaching the nkg2d-binding portions of monovalent mica or micb protein, i.e. Their α1-α2 platform domain, to the intended target cell specifically.
|Peptides for vaccine|
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.. .
|Novel pd1 isoforms, and uses thereof for potentiating immune responses|
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
|Optimized anti-cd3 variable regions|
The present invention is directed to optimized anti-cd3 variable sequences for use in a variety of bispecific formats, including those that utilize scfv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector.
|Immunological targeting of pathological tau proteins|
The present invention relates to methods and compositions for treating, preventing, and diagnosing alzheimer's disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose alzheimer's disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject..
|Igy composition for use in celiac disease|
The present invention relates to an igy composition characterized in that said igy composition contains igy antibodies, fragments, and/or fab fragments thereof that specifically bind to a peptide with the amino acid sequence of seq id no: 1 and to the use of this igy composition in the therapy of celiac disease, rheumatism, and/or wheat allergy.. .
Described herein is a bispecific molecule containing an fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules..
|Anti-c-met tandem fc bispecific antibodies|
Provided herein are tandem fcs and tandem fc antibodies (“tfcas”), e.g., tandem fc bispecific antibodies (“tfcbas”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a tfc, which tfc comprises a first fc region and a second fc region, wherein the first and the second fc regions are linked through a tfc linker to form a contiguous polypeptide and dimerize to form an fc dimer.
|Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding|
The present invention is directed to methods and compositions for the production of fc-containing polypeptides which are useful as human or animal therapeutic agents, and which comprise increased anti-inflammatory properties and improved fcrn binding.. .
|Methods of treating periodontal inflammation and periodontal bone loss|
Methods and compositions for use in treating periodontitis include a del-1 polypeptide.. .
|Means and methods for treating angiogenesis-related diseases|
The present invention is concerned with a protein oligomer comprising at least two nc-1 monomers of human collagen 18 or fragments of an nc-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a nc-1 monomer of human collagen 18 and a fc domain of an immunoglobulin.
|Treating skin cancer|
This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-vegf polypeptide antibody to treat skin cancer are provided..
|Suppression of neuroendocrine diseases|
The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a ghrh receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a kiss-1 receptor or a prolactin-releasing peptide receptor.
|Chimeric factor vii molecules|
The present invention relates to chimeric factor vii polypeptides and methods of using the same.. .
|Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases|
Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (n)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (n)-terminus on a variant igf-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant igf-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant igf-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the igf2/ci-mpr receptor and cellular uptake using the methods disclosed herein.